Pyxis Oncology, Inc.

PYXS

US7473241013

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
4.34 ^USD	-3.77%		-0.91%	+141.11%

Mar. 22	H.C. Wainwright Adjusts Price Target on Pyxis Oncology to $7 From $4, Maintains Buy Rating	MT
Mar. 21	Health Care Up on Drug Sales Optimism -- Health Care Roundup	DJ

Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to NASDAQ Composite Index

October 11, 2021 at 12:00 am EDT

Pyxis Oncology, Inc. has been added to NASDAQ Composite Index (^COMP)

Latest news about Pyxis Oncology, Inc.

H.C. Wainwright Adjusts Price Target on Pyxis Oncology to $7 From $4, Maintains Buy Rating	Mar. 22	MT
Health Care Up on Drug Sales Optimism -- Health Care Roundup	Mar. 21	DJ
Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Pyxis Oncology, Inc. Appoints Santhosh Palani to Its Board of Directors	Mar. 13	CI
Pyxis Oncology Announces Private Placement of Shares, Pre-Funded Warrants to Raise $50 Million	Feb. 27	MT
Pyxis Oncology, Inc. announced that it expects to receive $49.999989 million in funding from Blue Owl Healthcare Opportunities, StemPoint Capital LP, Deep Track Capital, LP, Laurion Capital Management LP, Ridgeback Capital Management LLC and another investors	Feb. 25	CI
BTIG Initiates Pyxis Oncology With Buy Rating, $8 Price Target	Feb. 09	MT
Leerink Partners Initiates Coverage on Pyxis Oncology with Outperform Rating, $12 Price Target	Jan. 23	MT
HC Wainwright Starts Pyxis Oncology With Buy Rating, $4 Price Target	Nov. 30	MT
Pyxis Oncology, Inc. Appoints Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer	Nov. 28	CI
Pyxis Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Pyxis Oncology Shares Fall After CEO Sells Stock	23-09-19	MT
RBC Initiates Pyxis Oncology at Outperform With Speculative Risk, Sets Price Target at $7, Sees 'Favorable' Risk/Reward	23-09-05	MT
Pyxis Oncology Completes Acquisition of Apexigen	23-08-23	MT
Pyxis Oncology, Inc. Appoints Jakob Dupont as Independent Director to the Board of Directors	23-08-23	CI
Pyxis Oncology, Inc. completed the acquisition of Apexigen, Inc. from entities associated with Pfizer Inc., Lincoln Park Capital, LLC, managed by Laurion Capital Management LP, Bayer World Investments B.V. and others.	23-08-22	CI
Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Pyxis Oncology Doses First Subject in Phase 1 Trial of Immunotherapy Antibody Candidate	23-05-30	MT
Pyxis Oncology, Inc. Advances Pyx-106 and PYX-201 Clinical Programs	23-05-30	CI
Wall Street Set to Open Lower as Investors Await Progress on Debt-Ceiling Talks Ahead of Fed Minutes Release	23-05-24	MT
Sector Update: Health Care Stocks Mixed Premarket Wednesday	23-05-24	MT
Sector Update: Health Care	23-05-24	MT
Transcript : Apexigen, Inc., Pyxis Oncology, Inc. - M&A Call	23-05-24
US Futures Lower as Investors Eye Debt Ceiling Talks, Await Fed Minutes Release	23-05-24	MT
Top Premarket Gainers	23-05-24	MT

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - RBC Capital Markets Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.34 USD

Average target price

8 USD

Spread / Average Target

+84.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PYXIS ONCOLOGY, INC.	+141.11%	256M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+0.20%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.80%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs